ALK

2:21
Current treatment landscape for ALK-positive NSCLC
Marina Garassino
3:43
Biomarkers in NSCLC: a pathologist’s insight into PD-L1 and TMB
Alex Haragan
0:58
Challenges and treatment of CNS metastases in NSCLC
Sanjay Popat
3:16
Impact of new TKIs on NSCLC treatment planning
Nicolas Girard
1:23
Optimizing treatment of ALK+ NSCLC: clinical realities
Silvia Novello
1:34
Therapy sequencing in the current NSCLC treatment landscape
Nicolas Girard
1:34
Personalized therapy in thoracic malignancies
Dean Fennell
4:43
A new role for pharmacists in the personalized treatment of cancer patients?
Christine Walko
2:42
Off-label medication use in lung cancer
Federico Cappuzzo
1:26
Assessment and diagnostic workup for NSCLC in 2018
Nathan Penell
1:28
ATLANTIC: durvalumab in the fight against NSCLC
Marina Garassino
2:11
Economic impact of NGS for NSCLC diagnostics
Nathan Penell
3:22
Drugs with low response rates – should they always be offered to patients?
Jacob Kettle
2:16
IMpower150 update from ELCC: atezolizumab and bevacizumab improve survival
Martin Reck
1:25
Treating NSCLC with CNS involvement: TKIs with high penetrance
Marina Garassino
1:38
More focus is needed on subtypes of lung cancer that do not have FDA-approved targeted therapies
Ross Camidge
VJOncology is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

VJO needs the contact information you provide to inform you about our latest oncology news and videos, educational courses and industry supported content (some of which may be promotional in nature). You may unsubscribe from these communications at anytime. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy.

The content of VJOncology is intended for healthcare professionals